open access

Vol 10, Supp. A (2019)
Case report
Published online: 2019-04-26
Get Citation

Ruxolitinib withdrawal syndrome in a patient with myelofibrosis

Ilona Seferyńska1, Krzysztof Warzocha1
DOI: 10.5603/em.2019.0012
Affiliations
  1. Klinika Hematologii, Instytut Hematologii i Transfuzjologii, ul. Indiry Gandhi 14, 02–776 Warszawa,, ul. Indiry Gandhi 14, 02–776 Warszawa, Poland

open access

Vol 10, Supp. A (2019)
CASE REPORTS
Published online: 2019-04-26

Abstract

As an inhibitor of JAK1/JAK2 kinase, ruxolitinib is an effective drug for the treatment of patients with primary and secondary myelofibrosis. Around half such patients demonstrate recovery from the disease’s general symptoms and have their enlarged spleens reduced, together with having an extended survival time. Nevertheless, some patients suffer side effects which thus indicate that the drug is discontinued. In some cases a sudden discontinuation leads to ruxolitinib withdrawal syndrome presenting as a rapid relapse back to the disease symptoms before treatment, as well as rapid splenomegaly. Also rarely occurring, are severe haemodynamic disturbances requiring intensive care. We hereby present a case report of a patient in whom ruxolitinib was discontinued resulting in withdrawal syndrome appearance.

Abstract

As an inhibitor of JAK1/JAK2 kinase, ruxolitinib is an effective drug for the treatment of patients with primary and secondary myelofibrosis. Around half such patients demonstrate recovery from the disease’s general symptoms and have their enlarged spleens reduced, together with having an extended survival time. Nevertheless, some patients suffer side effects which thus indicate that the drug is discontinued. In some cases a sudden discontinuation leads to ruxolitinib withdrawal syndrome presenting as a rapid relapse back to the disease symptoms before treatment, as well as rapid splenomegaly. Also rarely occurring, are severe haemodynamic disturbances requiring intensive care. We hereby present a case report of a patient in whom ruxolitinib was discontinued resulting in withdrawal syndrome appearance.

Get Citation

Keywords

uxolitinib withdrawal syndrome, myelofibrosis

About this article
Title

Ruxolitinib withdrawal syndrome in a patient with myelofibrosis

Journal

Hematology in Clinical Practice

Issue

Vol 10, Supp. A (2019)

Article type

Case report

Pages

15-18

Published online

2019-04-26

DOI

10.5603/em.2019.0012

Keywords

uxolitinib withdrawal syndrome
myelofibrosis

Authors

Ilona Seferyńska
Krzysztof Warzocha

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.